The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model.

Yasin Bagheri, Mahshid Dehghan, Seyyedeh Mina Hejazian, Mohammadreza Ardalan, Sepideh Zununi Vahed, Bahram Niknafs
Author Information
  1. Yasin Bagheri: Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ORCID
  2. Mahshid Dehghan: Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ORCID
  3. Seyyedeh Mina Hejazian: Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ORCID
  4. Mohammadreza Ardalan: Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ORCID
  5. Sepideh Zununi Vahed: Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ORCID
  6. Bahram Niknafs: Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ORCID

Abstract

Introduction: Acute kidney injury (AKI) is a common clinical occurrence causing high mortality and morbidity. In acute renocardiac syndrome, AKI leads to acute cardiac injury or/and dysfunction. This study aimed to investigate the antioxidative effects of Edaravone on cardiac tissues following the induction of renal ischemia-reperfusion injury (IRI) in rats.
Methods: Twenty-four male Wistar rats were randomly divided into four groups: IR+Edaravone, Edaravone, IR, and Sham groups (six rats per group). Non-traumatic clamps were used to stop the artery and vein blood flow of the left kidney in rats of the IR groups for 45 minutes. Thirty minutes before ischemia induction, Edaravone (3 mg/kg) was injected intraperitoneally in the IR+Edaravone group. Cardiac samples were subjected to biochemical analyses.
Results: The Results showed a significant increase in the enzymatic activity of glutathione peroxidase (=0.01), catalase (=0.03), and superoxide dismutase (=0.02), and the levels of glutathione (=0.012), and total antioxidant capacity (<0.001) in the IR+Edaravone group in comparison to the IR group. Moreover, the total antioxidant capacity of the heart was increased in the Edaravone group compared to the control and IR groups (<0.001), indicating the safety of the drug.
Conclusion: The results can reveal important insights into the protective effects of Edaravone against acute renocardiac syndrome.

Keywords

References

  1. Eur Surg Res. 2013;51(1-2):21-32 [PMID: 23899611]
  2. Zhonghua Yi Xue Za Zhi. 2008 Sep 23;88(36):2558-61 [PMID: 19080651]
  3. Am J Cardiol. 2004 Aug 15;94(4):481-4 [PMID: 15325934]
  4. Int Immunopharmacol. 2023 Feb;115:109690 [PMID: 36640709]
  5. Int J Oncol. 2020 Aug;57(2):500-508 [PMID: 32626935]
  6. J Control Release. 2023 Jul;359:257-267 [PMID: 37290723]
  7. Pharmacol Res Perspect. 2024 Aug;12(4):e1228 [PMID: 38956898]
  8. Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93 [PMID: 23744003]
  9. Int J Pharm. 2024 Feb 15;651:123748 [PMID: 38154533]
  10. Redox Rep. 2015;20(6):275-81 [PMID: 25893851]
  11. Cardiovasc Drugs Ther. 2014 Apr;28(2):173-81 [PMID: 24532094]
  12. J Surg Res. 2007 Jan;137(1):69-74 [PMID: 17064733]
  13. Lancet. 2018 Nov 10;392(10159):2052-2090 [PMID: 30340847]
  14. Drug Des Devel Ther. 2020 Jan 15;14:175-183 [PMID: 32021102]
  15. Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):338-49 [PMID: 18461048]
  16. J Orthop Surg (Hong Kong). 2019 Sep-Dec;27(3):2309499019874470 [PMID: 31549573]
  17. Heliyon. 2023 Nov 13;9(11):e22273 [PMID: 38053866]
  18. Hypertension. 2003 Nov;42(5):1050-65 [PMID: 14604997]
  19. Curr Mol Pharmacol. 2024;17(1):e250823220363 [PMID: 37622553]
  20. Int Urol Nephrol. 2015 Oct;47(10):1745-52 [PMID: 26300162]
  21. Exp Ther Med. 2012 Jan;3(1):3-8 [PMID: 22969835]
  22. Clin J Am Soc Nephrol. 2008 Mar;3(2):491-504 [PMID: 18287250]
  23. J Int Med Res. 2006 Sep-Oct;34(5):475-84 [PMID: 17133776]
  24. Intensive Care Med. 2015 Aug;41(8):1411-23 [PMID: 26162677]
  25. Drug Deliv. 2017 Nov;24(1):962-978 [PMID: 28633547]
  26. Br J Pharmacol. 2004 Jun;142(3):618-26 [PMID: 15148265]
  27. Nat Rev Cardiol. 2017 Mar;14(3):133-144 [PMID: 27905474]
  28. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2514-8 [PMID: 16100244]
  29. J Thorac Cardiovasc Surg. 1985 Jul;90(1):68-72 [PMID: 2989620]
  30. J Cardiovasc Pharmacol. 2005 Jul;46(1):46-51 [PMID: 15965354]
  31. Turk Gogus Kalp Damar Cerrahisi Derg. 2020 Apr 22;28(2):274-281 [PMID: 32551157]
  32. Drug Des Devel Ther. 2018 Jul 09;12:2111-2128 [PMID: 30022810]
  33. J Pharm Pharmacol. 2023 Jun 5;75(6):819-827 [PMID: 35866843]
  34. Exp Ther Med. 2011 Sep;2(5):771-775 [PMID: 22977573]

Word Cloud

Created with Highcharts 10.0.0EdaravonegroupacutesyndromeratsIR=0kidneyinjuryrenocardiacIR+EdaravonegroupsAKIcardiaceffectsinductionischemia-reperfusionminutesglutathionetotalantioxidantcapacity<0001protectiveIntroduction:Acutecommonclinicaloccurrencecausinghighmortalitymorbidityleadsor/anddysfunctionstudyaimedinvestigateantioxidativetissuesfollowingrenalIRIMethods:Twenty-fourmaleWistarrandomlydividedfourgroups:ShamsixperNon-traumaticclampsusedstoparteryveinbloodflowleft45Thirtyischemia3mg/kginjectedintraperitoneallyCardiacsamplessubjectedbiochemicalanalysesResults:Resultsshowedsignificantincreaseenzymaticactivityperoxidase01catalase03superoxidedismutase02levels012comparisonMoreoverheartincreasedcomparedcontrolindicatingsafetydrugConclusion:resultscanrevealimportantinsightseffectmodelAntioxidantsCardiorenalIschemia-reperfusion

Similar Articles

Cited By

No available data.